Fig. 1: Potential delays in the pipeline for neurological therapeutic development resulting from the COVID-19 pandemic. | Nature Reviews Neurology

Fig. 1: Potential delays in the pipeline for neurological therapeutic development resulting from the COVID-19 pandemic.

From: COVID-19 and the neurological disease therapeutic pipeline

Fig. 1: Potential delays in the pipeline for neurological therapeutic development resulting from the COVID-19 pandemic.The alternative text for this image may have been generated using AI.

Time required for each stage of clinical therapeutic development and the potential impact of COVID-19 on the developmental timeline based on the observed effects of the pandemic so far. Direct COVID-19 impact is a reality, and will extend the timeline for preclinical research and all phases of subsequent development for ongoing trials by a year or more, depending on the duration of the pandemic. If delays, potential need for repetition of studies and reduced likelihood of research engagement remain problematic over the longer term, an average 15-year development programme could double to more than 30 years for drugs that are currently in the early preclinical phase.

Back to article page